Loading clinical trials...

A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery | Clinical Trials | Clareo Health

COMPLETED

A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery

Why Do Patients Agree To or Decline Adjuvant Immunotherapy and Are They Satisfied With Their Decision?

NCT03843593•Memorial Sloan Kettering Cancer Center

Summary

The purpose of this study is to find out what patients consider when deciding whether or not to receive adjuvant treatment, and how patients feel about their decision after one year.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients with stage IIIB, IIIC, IIID, or IV (AJCC, 8th edition) cutaneous melanoma rendered free of disease by surgical resection.
•Patients are being offered adjuvant nivolumab or pembrolizumab therapy
•Patient has not yet formally discussed their treatment options with their Medical Oncologist.
•Age 18 or older.
•Ability to speak and read English because we do not have the resources to translate materials into other languages.

Exclusion Criteria

•Patient not currently free of disease.
•Candidate for adjuvant dabrafenib/trametinib therapy.
•Patients who have received prior checkpoint inhibitor therapy.

Locations (3)

Memorial Sloan Kettering Basking Ridge (All Protocol Activities)

Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Westchester (All Protocol Activities)

Harrison, New York, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Key Dates

Start Date

February 14, 2019

Primary Completion Date

December 29, 2022

Completion Date

December 29, 2022

Last Updated

January 4, 2023

Enrollment

ACTUAL participants

Conditions

Cutaneous Melanoma

Interventions

Demographics Questionnaire

BEHAVIORAL

Adjuvant Treatment Beliefs Scale10

BEHAVIORAL

Functional Assessment of Cancer Therapy - Melanoma (FACT-M)11

BEHAVIORAL

Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - General (FACIT-TS-G)13

BEHAVIORAL

Decisional Regret14

BEHAVIORAL

Clinician Preference for Treatment

BEHAVIORAL

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

NCT05039801

Advanced Endometrial CarcinomaAdvanced Head and Neck Squamous Cell Carcinoma+36 more

View study

RECRUITINGNA

Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer

NCT06391099

Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Cutaneous Melanoma+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 4, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery

Inclusion Criteria

Exclusion Criteria

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer

Narrow Excision Versus Wide Excision for the Treatment of Adults With Invasive Cutaneous Melanoma, ICEMAN Trial

Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial

Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation